First-in-Human Evaluation of the Safety, Tolerability, and Pharmacokinetics of a Neuroprotective Poly (ADP‐ribose) Polymerase‐1 Inhibitor, JPI-289, in Healthy Volunteers

• Egile Nagusiak: Han S (Egilea), Kim YH (Egilea), Choi HY (Egilea), Soh DJ (Egilea), Kim J (Egilea), Nam J (Egilea), Kim JW (Egilea), Bae KS (Egilea), Lim HS (Egilea)
• Formatua: Liburua
• Argitaratua: Dove Medical Press, 2020-08-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Sungpil Han,1 Yo Han Kim,1 Hee Youn Choi,1 Dong-Jun Soh,2 Jeongmin Kim,2 Joonwoo Nam,2 Jong-Woo Kim,2 Kyun-Seop Bae,1 Hyeong-Seok Lim1 1Department of Clinical Pharmacology and Therapeutics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea; 2Clinical Development...